Venous thromboembolic diseases: diagnosis, management and thrombophilia testing

concurrently with a VKA for at least 5 days or until the INR is at least 2.0 in 2 consecutive readings, followed by a VKA on its own. Note the cautions and requirements for dose adjustment and monitoring in the medicine's SPC, and follow locally agreed protocols or advice from a specialist or multidisciplinary team. [2020] Anticoagulation treatment for DVT or PE with active cancer In March 2020, most anticoagulants were off label for the treatment of DVT or PE in people with active cancer. See NICE's information on prescribing medicines. 1.3.15 Offer people with active cancer and confirmed proximal DVT or PE anticoagulation treatment for 3 to 6 months. Review at 3 to 6 months according to clinical need. For recommendations on treatment after 3 to 6 months, see the section on long-term anticoagulation for secondary prevention. [2020] 1.3.16 When choosing anticoagulation treatment for people with active cancer and confirmed proximal DVT or PE, take into account the tumour site, interactions with other drugs including those used to treat cancer, and the person's bleeding risk. [2020] 1.3.17 Consider a direct-acting oral anticoagulant (DOAC) for people with active cancer and confirmed proximal DVT or PE. [2020] 1.3.18 If a DOAC
